Pharmaron Completes Strategic Investment in LinkStart
and Enters into Strategic Partnership Arrangement
Beijing, China, June 18，2019 — Pharmaron, a global leading life science services company headquartered in Beijing, and LinkStart SMO Ltd. (LinkStart), a clinical SMO headquartered in Beijing, announced today that Pharmaron completed a strategic investment and entered into a strategic partnership arrangement with LinkStart, aiming for a sustainable and deep strategic relationship.
LinkStart will become Pharmaron’s strategic partner for clinical development services in China. Both parties will make full use of their complementary strengths in technologies, resources and market access to better serve their partners in the clinical development area. This partnership strengthens Pharmaron’s clinical development service capabilities, which follows the acquisition of its clinical pharmacology center in Baltimore, Maryland in 2017 and the recent acquisition of a majority stake in CR Medicon. This investment facilitates the construction of the end-to-end service platform to support needs from drug discovery through to clinical development and accelerate the clinical development process.
Mr. Yang Liu, founder, Chairman and CEO of LinkStart, expressed his enthusiasm about this partnership. “LinkStart has been striving to provide high quality clinical SMO services to our partners, in addition to elevating the SMO industry’s standard in China by working closely with clinically relevant parties. We are excited to have Pharmaron, a highly experienced global player in the life science service industry, as our strategic investor and partner. With this strategic partnership, my team and I are confident to realize LinkStart’s long-term strategy, to better serve the life science industry by accelerating the clinical development process for innovative medicines and to become a world-renowned SMO brand.”
Mr. Larry Lou, President and COO of Pharmaron commented, “Our investment in LinkStart strengthens Pharmaron’s clinical development capabilities, which allows Pharmaron to be a step closer to providing fully integrated drug R&D service to our partners. This clinical SMO investment complements our recent strategic move with CR Medicon and together with our clinical pharmacology center and clinical metabolism labs in the USA and UK, we can better support our partners’ clinical development needs both domestically and globally.”
About LinkStart
LinkStart is a privately owned, leading clinical SMO in China. Founded in 2012, headquartered in Beijing, LinkStart has established stable and long term collaboration relationship with over 500 national clinical research centers in China. It has a branch in Nanjing, and business offices in Shanghai, Nanjing, Guangzhou, Hangzhou, Chengdu, Haerbin, Hefei, Wuhan, Xi’an, etc, covering 110+ cities in China. The company has conducted 400+ studies, of which 85% are the 1stclass of new drugs and biological products. LinkStart is particularly experienced in conducting clinical research for drugs against cancer, endocrinological diseases, cardiovascular diseases, infection and immune rheumatoid diseases.
About Pharmaron
Pharmaron (China’s A-share Market: 300759) is a public-owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, chemical & pharmaceutical development to clinical CRO. With over 6,800 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
康龙化成完成对联斯达的战略投资
并与联斯达建立战略合作关系
中国，北京，2019年6月18日—康龙化成宣布战略性投资北京联斯达医药科技发展有限公司（提供第三方独立临床研究现场管理服务（SMO），总部位于北京，英文名：LinkStart SMO Ltd.以下简称联斯达），并建立战略合作关系，致力于可持续发展及深层次的合作。
通过此次联手，联斯达将成为康龙化成临床开发服务领域的战略合作伙伴，双方将充分发挥各自技术、资源及市场方面的优势，为客户提供更加优良的临床开发服务。 这是康龙化成继2017年收购美国马里兰州巴尔的摩临床药理中心（CPC），以及近期取得南京希麦迪（立足于中国市场的临床CRO公司）控股权之后，在增强临床服务能力方面的又一布局。此举将进一步完善公司的临床开发服务平台，丰富公司一体化药物研发服务内容，加快药物临床开发进程。
联斯达创始人、董事长兼CEO刘洋先生对该战略合作表示非常期待：“联斯达一直致力于为合作伙伴提供高质量的临床SMO服务，与业界临床相关机构保持密切合作关系，共同提升中国SMO行业水准。我们很高兴有康龙化成这样一家在国际生命科学研发服务领域具有丰富经验的企业作为我们的投资人及战略合作伙伴。我和团队将更有信心实现联斯达的长远战略目标，服务于生命科学产业，加快创新药的临床开发进程，打造中国SMO的世界品牌。”
康龙化成总裁兼COO楼小强先生表示：“通过投资联斯达并建立战略合作关系，我们的临床开发服务能力得到进一步延伸和提高，进一步丰富和夯实了我们的全流程、一体化研发服务平台。此次针对临床SMO服务的投资，是继近期追加投资希麦迪之后的系列举措之一，结合我们的临床药理中心，以及英美两地的临床代谢试验室，我们有信心为国内外客户提供优质的临床开发服务！”
关于联斯达
联斯达成立于2012年，是国内临床研究现场管理组织（SMO）领导者之一。联斯达与中国500多家国家药物临床试验机构均达成了稳定的合作关系，总部设在北京，在南京设有分公司，并在上海、南京、广州、杭州、成都、哈尔滨、合肥、武汉、西安等城市建立办事处，覆盖中国城市110+。公司至今服务项目达400+，85%为1类新药和生物制品，擅长肿瘤、内分泌、心脑血管、抗感染和风湿免疫领域。
关于康龙化成
康龙化成新药技术股份有限公司(股票代码：300759)，成立于2004年，是国际领先的生命科学研发服务企业。经过十多年的快速发展，康龙化成打造了全方位的药物研发一体化平台，贯穿合成与合成及药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、放射标记化学、放射标记代谢、临床药理、临床分析、原料药和成品药的工艺优化及生产、临床CRO等领域。康龙化成在中国、美国、英国均有运营实体，拥有6,800多名员工，一流的人才队伍，高质量的研发服务，获得了业界的广泛认可，与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。
详情请访问公司网站：www.pharmaron.com
